INDAPTUS THERAPEUTICS INC. - COMMON STOCK

0.9500

10-January-25 16:45:00

15 minutes delayed

Stocks

-0.0200

-2.06%

Today's range

0.9119 - 1.0000

ISIN

N/A

Source

NASDAQ

Indaptus Therapeutics Provides Year-End Review and Outlook for 2025

08 Jan 2025 08:00:00 By Nasdaq GlobeNewswire
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement

22 Nov 2024 08:36:14 By Nasdaq GlobeNewswire
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

12 Nov 2024 08:00:01 By Nasdaq GlobeNewswire
Indaptus Therapeutics’ Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology

11 Nov 2024 08:00:00 By Nasdaq GlobeNewswire
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting

07 Nov 2024 08:00:01 By Nasdaq GlobeNewswire
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences

23 Oct 2024 08:00:01 By Nasdaq GlobeNewswire
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

22 Oct 2024 08:00:01 By Nasdaq GlobeNewswire
Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data

15 Oct 2024 08:00:00 By Nasdaq GlobeNewswire

<<
<
1
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.